Prof. Jonathan Rabinowitz, of the Louis and Gabi Weisfeld School of Social Work, has extensive experience in studying effectiveness, efficacy, efficiency and safety of antipsychotic medications based on data from clinical trials, pragmatic trials, and national case registries.
He studies the epidemiology and etiology of severe mental illness, particularly premorbid functioning, cognitive functioning, perinatal and developmental risk factors and long-term course, in population based cohorts and case registries.
Rabinowitz is an active member of NEWMEDS (New Medications in Depression and Schizophrenia), an international consortium of scientists and pharmaceutical leaders dedicated to developing effective drugs for the treatment of schizophrenia and depression.
Rabinowitz heads the Working Group on Advanced Data Analysis Techniques, which develops and tests advanced data analysis techniques for shorter and more efficient clinical trials with antipsychotic and antidepressant medications.
NEWMEDS is funded by the Innovative Medicines Initiative, a young and unique public-private partnership between the pharmaceutical industry (represented by the European Federation of Pharmaceutical Industries and Associations, EFPIA) and the European Union (represented by the European Commission).
The major foci of Rabinowitz’s current work are to identify the optimal duration that reduces patient exposure and maximises efficacy information in drug trials; Identify measures most sensitive to distinguishing active treatment vs. placebo-response; Develop designs for more efficient trials by combining statistical tests of outcomes and optimizing symptom scales; Analyze trajectories of treatment response (rather than simple responder/non-responder status) to identify and link to emerging biomarkers.
This work builds on Rabinowitz’s large scale meta-analysis recently completed, in which he has demonstrated that dropout is highly problematic in clinical trials of antipsychotic medications, and should not be ignored as it relates to outcomes. He has also proposed and tested a method for accounting for it in statistical analyses that make no assumptions about the nature of the missing data.
To date, Rabinowitz’s group has amassed a repository of clinical trial data on over 23,000 patients from 67 trials on 11 antipsychotic compounds spanning 25 countries provided by five major pharmaceutical companies. A similar repository of clinical trial data on antidepressant drugs is in process.
This data resource is being used to test the analytic strategies being developed. These data repositories are the largest of their kind in the world.